Effect of mizoribine in children with inflammatory bowel disease.
Department of Pediatrics and Adolescent Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.
Tohru
T
Fujii
Yoshikazu
Y
Ohtsuka
Yoko
Y
Yamakawa
Kiyotaka
K
Ohtani
Takahiro
T
Kudo
Yoshiyuki
Y
Ohtomo
Satoru
S
Nagata
Toshiaki
T
Shimizu
D000284:Administration, Oral; D000293:Adolescent; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003424:Crohn Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008134:Long-Term Care; D012263:Ribonucleosides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine